Jul 20, 2026 7:55 AM Eastern Daylight Time Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000 Immunomic Therapeutics Announces First Patient Dosed in ...
Jun 15, 2026 7:55 AM Eastern Daylight Time ITI Announces PMDA Clearance of CTN for a UNITE®-Based Self-Amplifying RNA Treatment for Japanese Red Cedar Allergy Company to Initiate First-in-Human Phase ...
Jan 20, 2026 12:03 PM Eastern Standard Time Immunomic Therapeutics Announces FDA Clearance of IND Application for a UNITE®-Based Self-Amplifying RNA Vaccine for Triple-Negative Breast Cancer, to Be Studied Alone ...
Immunomic Therapeutics Announces Presentation on Self-amplifying RNA vaccines using the UNITE® platform for Triple-negative Breast Cancer at SITC 39th Annual Meeting 2024 Click here for details: https://ow.ly/Se7750U1mUt
Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma ITI-3000 Demonstrated a Favorable Safety and Tolerability Profile Patients showed ...
Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme -Top-Line Data Expected in the Second Quarter of ...
March 06, 2023 09:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that ...
This meeting will feature in-person presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, ...
January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that ...
Vaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a company that engineers precision delivery systems that overcome ...
November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced ...
October 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today ...